title: Transmission of HIV in the dental clinic and elsewhere.
abstract: This review focuses on the risk of transmission of HIV in dental practice in developed and developing countries; and as a result of oral sex, perinatal transmission and breast feeding. Postexposure prophylaxis (PEP) and practical measures to control cross-infection with TB are also discussed. There are few data from resource-poor countries where prevalence of HIV and risk of infection are higher--issues that deserve priority. Available information indicates that the risk of HIV transmission in the dental office is very low. Transmission of HIV from three healthcare workers to patients has been confirmed, including a dentist who infected six patients. There are >300 reports (102 confirmed) of occupational transmission to healthcare workers, including nine dental workers (unconfirmed). Exposure to HIV has been reported by 0.5% dentists/year. The risk of HIV infection after percutaneous exposure (0.3%) can be reduced by 81% with zidovudine PEP. However, risk assessment is required to assess the need and appropriate regimen. The risk of HIV transmission associated with orogenital sex exists, but is considered extremely low: barrier protection is recommended. Conversely, the proportion of babies who acquire HIV from untreated HIV-seropositive mothers is 15-25% in developed countries and 25-45% in developing countries. The frequency of HIV transmission attributable to breastfeeding is 16%. Airborne transmission of TB can be avoided by the prompt referral of known/suspected cases of active TB for chemotherapy, deferral of elective procedures until patients are not infectious, and the use of appropriate standard/isolation precautions including adequate ventilation of treatment areas.
authors.affiliation: School of Dentistry and Department of Epidemiology, Faculty of Medicine & Dentistry, The University of Western Ontario, London, Canada. gmccarth@uwo.ca
authors.forename: Gillian M
authors.initials: GM
authors.lastname: McCarthy
authors.forename: C S
authors.initials: CS
authors.lastname: Ssali
authors.forename: H
authors.initials: H
authors.lastname: Bednarsh
authors.forename: J
authors.initials: J
authors.lastname: Jorge
authors.forename: K
authors.initials: K
authors.lastname: Wangrangsimakul
authors.forename: K
authors.initials: K
authors.lastname: Page-Shafer
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000517:prevention & control; D019380:Anti-HIV Agents / Q000627:therapeutic use; D001942:Breast Feeding; D003428:Cross Infection / Q000517:prevention & control; D003740:Dental Clinics; D019049:Developed Countries; D003906:Developing Countries; D005260:Female; D015658:HIV Infections / Q000517:prevention & control / Q000635:transmission*; D006801:Humans; D007223:Infant; D019552:Infection Control, Dental; D017758:Infectious Disease Transmission, Patient-to-Professional; D017757:Infectious Disease Transmission, Professional-to-Patient; D018445:Infectious Disease Transmission, Vertical; D009784:Occupational Diseases / Q000517:prevention & control; D016273:Occupational Exposure; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000517:prevention & control; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D012307:Risk Factors; D012725:Sexual Behavior; D014376:Tuberculosis / Q000517:prevention & control; D015215:Zidovudine / Q000627:therapeutic use
chemical_list: D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine